once a week insulin drug, page-10

Dougal - I agree entirely with your post. As with any company there are products under development for the long term (insulin) and the short term.

But the key difference b/n POH and so many other Biotechs that are listed here is we have a rich and diverse pipeline in the clinic. We are not a "one trick pony" relying on success from one idea. Should we have a set back in one area as we did with nestle last year when we didnt achieve Nestles markers - we then continue on with our other programs. That should instill plenty of confidence in this stock for newcomers to this story

KC